JP2014507950A - 混合個体群における標的ｄｎａを配列決定するためのキットおよび方法 - Google Patents
混合個体群における標的ｄｎａを配列決定するためのキットおよび方法 Download PDFInfo
- Publication number
- JP2014507950A JP2014507950A JP2013556801A JP2013556801A JP2014507950A JP 2014507950 A JP2014507950 A JP 2014507950A JP 2013556801 A JP2013556801 A JP 2013556801A JP 2013556801 A JP2013556801 A JP 2013556801A JP 2014507950 A JP2014507950 A JP 2014507950A
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- strand
- sequence
- sequencing
- target
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000012163 sequencing technique Methods 0.000 title claims abstract description 195
- 238000000034 method Methods 0.000 title claims abstract description 81
- 230000035772 mutation Effects 0.000 claims abstract description 65
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 16
- 230000002438 mitochondrial effect Effects 0.000 claims abstract description 14
- 150000007523 nucleic acids Chemical class 0.000 claims description 206
- 102000039446 nucleic acids Human genes 0.000 claims description 182
- 108020004707 nucleic acids Proteins 0.000 claims description 182
- 230000000903 blocking effect Effects 0.000 claims description 127
- 238000006243 chemical reaction Methods 0.000 claims description 56
- 230000000295 complement effect Effects 0.000 claims description 54
- 239000011541 reaction mixture Substances 0.000 claims description 46
- 108020004414 DNA Proteins 0.000 claims description 44
- 125000003729 nucleotide group Chemical group 0.000 claims description 41
- 101100193693 Kirsten murine sarcoma virus K-RAS gene Proteins 0.000 claims description 33
- 238000001514 detection method Methods 0.000 claims description 32
- 239000002773 nucleotide Substances 0.000 claims description 32
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 23
- 230000003321 amplification Effects 0.000 claims description 22
- 238000004925 denaturation Methods 0.000 claims description 18
- 230000036425 denaturation Effects 0.000 claims description 18
- 239000000203 mixture Substances 0.000 claims description 15
- 238000002844 melting Methods 0.000 claims description 13
- 230000008018 melting Effects 0.000 claims description 13
- 238000001712 DNA sequencing Methods 0.000 claims description 11
- 108091027305 Heteroduplex Proteins 0.000 claims description 11
- 101000984753 Homo sapiens Serine/threonine-protein kinase B-raf Proteins 0.000 claims description 9
- 108091093037 Peptide nucleic acid Proteins 0.000 claims description 9
- 102100027103 Serine/threonine-protein kinase B-raf Human genes 0.000 claims description 9
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 claims description 8
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 claims description 8
- 108060002716 Exonuclease Proteins 0.000 claims description 7
- 229910019142 PO4 Inorganic materials 0.000 claims description 7
- 230000015572 biosynthetic process Effects 0.000 claims description 7
- 102000013165 exonuclease Human genes 0.000 claims description 7
- 239000010452 phosphate Substances 0.000 claims description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 6
- 108020004705 Codon Proteins 0.000 claims description 6
- 238000012175 pyrosequencing Methods 0.000 claims description 4
- 230000001419 dependent effect Effects 0.000 claims description 3
- 235000011178 triphosphate Nutrition 0.000 claims description 3
- 239000001226 triphosphate Substances 0.000 claims description 3
- 230000000593 degrading effect Effects 0.000 claims description 2
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 claims description 2
- 208000035177 MELAS Diseases 0.000 claims 1
- 238000012165 high-throughput sequencing Methods 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 abstract description 18
- 201000011510 cancer Diseases 0.000 abstract description 13
- 241000700605 Viruses Species 0.000 abstract description 3
- 238000011275 oncology therapy Methods 0.000 abstract 1
- 239000000523 sample Substances 0.000 description 39
- 238000001962 electrophoresis Methods 0.000 description 24
- 241000701806 Human papillomavirus Species 0.000 description 17
- 210000004027 cell Anatomy 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- 102200006531 rs121913529 Human genes 0.000 description 10
- 238000009396 hybridization Methods 0.000 description 9
- 108091034117 Oligonucleotide Proteins 0.000 description 8
- 102200055464 rs113488022 Human genes 0.000 description 8
- 206010069754 Acquired gene mutation Diseases 0.000 description 7
- 102000053602 DNA Human genes 0.000 description 7
- 102200055537 rs121913355 Human genes 0.000 description 7
- 230000037439 somatic mutation Effects 0.000 description 7
- 108700028369 Alleles Proteins 0.000 description 6
- 239000002299 complementary DNA Substances 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 102200006540 rs121913530 Human genes 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 238000013461 design Methods 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 238000003556 assay Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 238000006366 phosphorylation reaction Methods 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 238000004393 prognosis Methods 0.000 description 4
- 238000004448 titration Methods 0.000 description 4
- 208000010444 Acidosis Diseases 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 3
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 3
- 206010058799 Mitochondrial encephalomyopathy Diseases 0.000 description 3
- 108020004682 Single-Stranded DNA Proteins 0.000 description 3
- 230000007950 acidosis Effects 0.000 description 3
- 208000026545 acidosis disease Diseases 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 102000040430 polynucleotide Human genes 0.000 description 3
- 108091033319 polynucleotide Proteins 0.000 description 3
- 239000002157 polynucleotide Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 108020004635 Complementary DNA Proteins 0.000 description 2
- 102000001301 EGF receptor Human genes 0.000 description 2
- 108060006698 EGF receptor Proteins 0.000 description 2
- 108020005196 Mitochondrial DNA Proteins 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000010804 cDNA synthesis Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 239000005546 dideoxynucleotide Substances 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000007480 sanger sequencing Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 108090001008 Avidin Proteins 0.000 description 1
- 108020000946 Bacterial DNA Proteins 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 229940122558 EGFR antagonist Drugs 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 201000002169 Mitochondrial myopathy Diseases 0.000 description 1
- 108091061939 Selfish DNA Proteins 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000002457 bidirectional effect Effects 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 239000003560 cancer drug Substances 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000000104 diagnostic biomarker Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
- 238000012606 in vitro cell culture Methods 0.000 description 1
- 208000023692 inborn mitochondrial myopathy Diseases 0.000 description 1
- 238000009830 intercalation Methods 0.000 description 1
- 208000006443 lactic acidosis Diseases 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- -1 nucleotide triphosphates Chemical class 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229960001972 panitumumab Drugs 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 239000013535 sea water Substances 0.000 description 1
- 238000011896 sensitive detection Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000011451 sequencing strategy Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- 238000007671 third-generation sequencing Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6869—Methods for sequencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
- C12Q1/708—Specific hybridization probes for papilloma
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2563/00—Nucleic acid detection characterized by the use of physical, structural and functional properties
- C12Q2563/173—Nucleic acid detection characterized by the use of physical, structural and functional properties staining/intercalating agent, e.g. ethidium bromide
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161447490P | 2011-02-28 | 2011-02-28 | |
| US61/447,490 | 2011-02-28 | ||
| US201161532887P | 2011-09-09 | 2011-09-09 | |
| US61/532,887 | 2011-09-09 | ||
| PCT/US2012/026938 WO2012118802A1 (en) | 2011-02-28 | 2012-02-28 | Kit and method for sequencing a target dna in a mixed population |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014507950A true JP2014507950A (ja) | 2014-04-03 |
| JP2014507950A5 JP2014507950A5 (enExample) | 2015-04-16 |
Family
ID=45815993
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013556801A Pending JP2014507950A (ja) | 2011-02-28 | 2012-02-28 | 混合個体群における標的ｄｎａを配列決定するためのキットおよび方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20120225421A1 (enExample) |
| EP (1) | EP2681332A1 (enExample) |
| JP (1) | JP2014507950A (enExample) |
| KR (1) | KR20140010093A (enExample) |
| CN (1) | CN103517993A (enExample) |
| AU (1) | AU2012223438A1 (enExample) |
| CA (1) | CA2828535A1 (enExample) |
| WO (1) | WO2012118802A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2018512878A (ja) * | 2015-04-20 | 2018-05-24 | ネオゲノミクス ラボラトリーズ， インコーポレイテッド | 次世代シークエンシングの感度を高めるための方法 |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2665500T3 (es) | 2010-03-08 | 2018-04-26 | Dana-Farber Cancer Institute, Inc. | Enriquecimiento de una PCR por COLD completa con secuencia de bloqueo de referencia |
| DK2691541T3 (en) | 2011-03-31 | 2018-01-22 | Dana Farber Cancer Inst Inc | PROCEDURE FOR ENRICHMENT OF SINGLE DRAWED MUTANTS SEQUENCES FROM A MIXTURE OF WILD TYPE AND MUTANTS |
| WO2014089797A1 (zh) * | 2012-12-13 | 2014-06-19 | 深圳华大基因科技服务有限公司 | 用于高通量测序的锁核酸修饰的dna片段 |
| WO2015013166A1 (en) | 2013-07-24 | 2015-01-29 | Dana-Farber Cancer Institute, Inc. | Methods and compositions to enable enrichment of minor dna alleles by limiting denaturation time in pcr or simply enable enrichment of minor dna alleles by limiting denaturation time in pcr |
| KR20160003444A (ko) * | 2014-07-01 | 2016-01-11 | 주식회사 유진셀 | 핵산말단분해효소를 이용한 서열-특이적 핵산 검출 방법 및 장치와 이에 사용되는 키트 |
| US10011869B2 (en) * | 2015-03-06 | 2018-07-03 | Pillar Biosciences Inc. | Selective amplification of overlapping amplicons |
| KR20170136555A (ko) * | 2015-04-15 | 2017-12-11 | 더 제너럴 하스피탈 코포레이션 | Lna-기반 돌연변이체 농축 차세대 서열분석 검정 |
| WO2017070339A1 (en) * | 2015-10-20 | 2017-04-27 | Richardson Katherine | Microfluidic device for enrichment of nucleic acid sequence alterations |
| CA3046953A1 (en) | 2016-12-12 | 2018-06-21 | Dana Farber Cancer Institute, Inc. | Compositions and methods for molecular barcoding of dna molecules prior to mutation enrichment and/or mutation detection |
| WO2019023243A1 (en) | 2017-07-24 | 2019-01-31 | Dana-Farber Cancer Institute, Inc. | METHODS AND COMPOSITIONS FOR SELECTING AND AMPLIFYING DNA TARGETS IN A SINGLE REACTION MIXTURE |
| CN109536594B (zh) * | 2017-09-20 | 2022-11-01 | 深圳华大智造科技股份有限公司 | 一种用于Small RNA的测序方法、测序试剂和应用 |
| ES2981912T3 (es) * | 2019-07-11 | 2024-10-11 | Univ Tokyo Science Found | Método para amplificar un ácido nucleico usando un portador en fase sólida |
| CN113567404A (zh) * | 2021-06-11 | 2021-10-29 | 上海交通大学 | 一种分析肿瘤细胞耐药性的方法和试剂盒 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002517210A (ja) * | 1998-05-30 | 2002-06-18 | ビジブル ジェネティクス インコーポレイテッド | ヒトパピローマウイルスの遺伝子型決定のための方法、試薬およびキット |
| JP2007530026A (ja) * | 2004-03-26 | 2007-11-01 | キアゲン アーエス | 核酸配列決定 |
| WO2011000997A1 (es) * | 2009-07-02 | 2011-01-06 | Consejo Superior De Investigaciones Científicas (Csic) | QUIMERA DE ADN POLIMERASA DEL FAGO φ 29 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2293238A (en) * | 1994-09-13 | 1996-03-20 | Inceltec Ltd | Primers for replication and/or amplification reactions |
| US5849497A (en) * | 1997-04-03 | 1998-12-15 | The Research Foundation Of State University Of New York | Specific inhibition of the polymerase chain reaction using a non-extendable oligonucleotide blocker |
| FR2779154B1 (fr) * | 1998-05-27 | 2002-07-12 | Bio Merieux | Procede d'amplification d'au moins une sequence nucleotidique particuliere et amorces de mise en oeuvre |
| DE10012540B4 (de) * | 2000-03-15 | 2004-09-23 | Vermicon Ag | Oligonukleotide und Verfahren zum spezifischen Nachweis von Mikroorganismen durch Polymerase-Kettenreaktion |
| CN1293204C (zh) * | 2000-08-30 | 2007-01-03 | 戴诺生物技术有限公司 | 等位基因的测定方法 |
| DK2183379T3 (en) * | 2007-08-01 | 2015-07-27 | Dana Farber Cancer Inst Inc | ENRICHMENT OF A TARGET SEQUENCE |
| US8071338B2 (en) * | 2007-08-08 | 2011-12-06 | Roche Molecular Systems, Inc. | Suppression of amplification using an oligonucleotide and a polymerase significantly lacking 5′-3′ nuclease activity |
| CN102470136B (zh) | 2009-07-29 | 2013-12-25 | 内尔维阿诺医学科学有限公司 | Plk 抑制剂的盐类 |
| ES2665500T3 (es) | 2010-03-08 | 2018-04-26 | Dana-Farber Cancer Institute, Inc. | Enriquecimiento de una PCR por COLD completa con secuencia de bloqueo de referencia |
-
2012
- 2012-02-28 CN CN201280020801.3A patent/CN103517993A/zh active Pending
- 2012-02-28 JP JP2013556801A patent/JP2014507950A/ja active Pending
- 2012-02-28 EP EP12708466.3A patent/EP2681332A1/en not_active Withdrawn
- 2012-02-28 KR KR1020137025264A patent/KR20140010093A/ko not_active Withdrawn
- 2012-02-28 US US13/407,274 patent/US20120225421A1/en not_active Abandoned
- 2012-02-28 CA CA2828535A patent/CA2828535A1/en not_active Abandoned
- 2012-02-28 AU AU2012223438A patent/AU2012223438A1/en not_active Abandoned
- 2012-02-28 WO PCT/US2012/026938 patent/WO2012118802A1/en not_active Ceased
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002517210A (ja) * | 1998-05-30 | 2002-06-18 | ビジブル ジェネティクス インコーポレイテッド | ヒトパピローマウイルスの遺伝子型決定のための方法、試薬およびキット |
| JP2007530026A (ja) * | 2004-03-26 | 2007-11-01 | キアゲン アーエス | 核酸配列決定 |
| WO2011000997A1 (es) * | 2009-07-02 | 2011-01-06 | Consejo Superior De Investigaciones Científicas (Csic) | QUIMERA DE ADN POLIMERASA DEL FAGO φ 29 |
Non-Patent Citations (2)
| Title |
|---|
| JPN6016001587; '標準技術集（核酸の増幅および検出）データベース：lambdaエキソヌクレアーゼ法' 特許庁ホームページ , 20010828 * |
| JPN7016000083; Ｎｕｃｌｅｉｃ Ａｃｉｄｓ Ｒｅｓｅａｒｃｈ Ｖｏｌ． ３９， Ｎｏ． １, 20101011, ｐ． ｅ２ * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2018512878A (ja) * | 2015-04-20 | 2018-05-24 | ネオゲノミクス ラボラトリーズ， インコーポレイテッド | 次世代シークエンシングの感度を高めるための方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2012118802A1 (en) | 2012-09-07 |
| AU2012223438A1 (en) | 2013-09-26 |
| EP2681332A1 (en) | 2014-01-08 |
| KR20140010093A (ko) | 2014-01-23 |
| CN103517993A (zh) | 2014-01-15 |
| CA2828535A1 (en) | 2012-09-07 |
| US20120225421A1 (en) | 2012-09-06 |
| WO2012118802A9 (en) | 2013-07-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2021202766B2 (en) | Method of preparing cell free nucleic acid molecules by in situ amplification | |
| JP2014507950A (ja) | 混合個体群における標的ｄｎａを配列決定するためのキットおよび方法 | |
| US10329605B2 (en) | Method to increase sensitivity of detection of low-occurrence mutations | |
| JP7384459B2 (ja) | ヌクレアーゼ協同ｐｃｒ原理に基づいて低存在比のｄｎａ突然変異を濃縮する検出技術システムおよび使用 | |
| JP6652693B2 (ja) | ブロッキングオリゴヌクレオチドを用いたｄｎａ増幅の方法 | |
| US8679788B2 (en) | Methods for the detection of nucleic acid differences | |
| CN107034277B (zh) | 一种检测低丰度基因突变的方法 | |
| WO2019178346A1 (en) | Enrichment of nucleic acids | |
| WO2019062614A1 (en) | METHOD FOR AMPLIFYING TARGET NUCLEIC ACID | |
| CN112824535A (zh) | 基因突变多重检测用引物组合物及其试剂盒 | |
| EP3494236B1 (en) | Method for conducting early detection of colon cancer and/or of colon cancer precursor cells and for monitoring colon cancer recurrence | |
| EP3350347B1 (en) | Methods and materials for detection of mutations | |
| JP2003518951A (ja) | 多型核酸配列の同時増幅およびリアルタイム検出のための方法 | |
| US20230374574A1 (en) | Compositions and methods for highly sensitive detection of target sequences in multiplex reactions | |
| CN110964833B (zh) | 一种一管检测血浆游离dna中kras和braf基因突变的试剂盒 | |
| Su et al. | Sensitive and selective detections of codon 12 and 13 KRAS mutations in a single tube using modified wild-type blocker | |
| WO2016103727A1 (ja) | 特異的核酸配列の増幅促進方法 | |
| JP2024059627A (ja) | 核酸の増幅のための試薬、混合物、キット、および方法 | |
| WO2022167794A1 (en) | Method for enriching nucleic acids | |
| KR20220085748A (ko) | 유방암 유전자 돌연변이 초고감도 선택적 증폭 방법 및 이를 위한 조성물 | |
| WO2006051991A1 (ja) | 核酸の増幅および検出方法 | |
| WO2006051990A1 (ja) | 核酸増幅を用いた診断方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20131031 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140114 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150227 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20150302 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150409 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160120 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20160419 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160613 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160617 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20161031 |